Literature DB >> 10889199

Retrovirally mediated transfer of a G protein-coupled receptor kinase (GRK) dominant-negative mutant enhances endogenous calcitonin receptor signaling in Chinese hamster ovary cells. GRK inhibition enhances expression of receptors and receptor mRNA.

K Horie1, P A Insel.   

Abstract

G protein-coupled receptor kinases (GRKs) initiate pathways leading to agonist-dependent phosphorylation and desensitization of G protein-coupled receptors. However, the role of GRKs in modulation of signaling properties of native receptors has not been clearly defined. Here we addressed this question by generating Chinese hamster ovary (CHO) cells stably expressing a dominant-negative mutant of GRK2 (DN-GRK2), K220R, using retrovirally mediated gene transfer, and we assessed function of the endogenously expressed calcitonin (CT) receptors. We found that CT-mediated responses were prominently enhanced in CHO cells expressing DN-GRK2 compared with mock-infected control CHO cells with approximately 3-fold increases in CT-promoted cAMP production in whole cells and adenylyl cyclase activity in membrane fractions. CT-promoted phosphoinositide hydrolysis was also enhanced in DN-GRK2 cells. The number of CT receptors was increased approximately 3-fold in DN-GRK2 cells, as assessed by (125)I-salmon CT-specific binding, and this was associated with increased CT receptor mRNA levels. These results indicate that DN-GRK2 has multiple consequences for CT receptor signaling, but a primary effect is an increase in CT receptor mRNA and receptor number and, in turn, enhanced CT receptor signaling. As such, our findings provide a mechanistic basis for previous observations regarding agonist-promoted down-regulation of CT receptors and for resistance and escape from response to CT in vitro and in vivo. Moreover, the data suggest that blunting of receptor desensitization by DN-GRK2 blocks a GRK-mediated tonic inhibition of CT receptor expression and response. We speculate that GRKs play a similar role for other G protein-coupled receptors as well.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10889199     DOI: 10.1074/jbc.M003413200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Altered expression and subcellular distribution of GRK subtypes in the dopamine-depleted rat basal ganglia is not normalized by l-DOPA treatment.

Authors:  M Rafiuddin Ahmed; Evgeny Bychkov; Vsevolod V Gurevich; Jeffrey L Benovic; Eugenia V Gurevich
Journal:  J Neurochem       Date:  2007-11-07       Impact factor: 5.372

2.  Expression of a G protein-coupled receptor (GPCR) leads to attenuation of signaling by other GPCRs: experimental evidence for a spontaneous GPCR constitutive inactive form.

Authors:  Maria Rosario Tubio; Natalia Fernandez; Carlos Patricio Fitzsimons; Sabrina Copsel; Sergio Santiago; Carina Shayo; Carlos Davio; Federico Monczor
Journal:  J Biol Chem       Date:  2010-03-18       Impact factor: 5.157

3.  Differential temporal and spatial regulation of somatostatin receptor phosphorylation and dephosphorylation.

Authors:  Madhumita Ghosh; Agnes Schonbrunn
Journal:  J Biol Chem       Date:  2011-02-22       Impact factor: 5.157

4.  Roles of phosphorylation-dependent and -independent mechanisms in the regulation of histamine H2 receptor by G protein-coupled receptor kinase 2.

Authors:  Natalia Fernandez; Federico L Gottardo; Maria N Alonso; Federico Monczor; Carina Shayo; Carlos Davio
Journal:  J Biol Chem       Date:  2011-06-24       Impact factor: 5.157

5.  Arrestins and two receptor kinases are upregulated in Parkinson's disease with dementia.

Authors:  E R Bychkov; V V Gurevich; J N Joyce; J L Benovic; E V Gurevich
Journal:  Neurobiol Aging       Date:  2006-11-27       Impact factor: 4.673

6.  G protein-coupled receptor kinase 6 (GRK6) selectively regulates endogenous secretin receptor responsiveness in NG108-15 cells.

Authors:  Roxana S Ghadessy; Jonathon M Willets; Eamonn Kelly
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.